In an effort to support global initiatives to contain the spread of the new coronavirus (COVID-19), the Academy is moving to an online platform or postponing all meetings and events intended to be held in person through April 30, 2020. Please check here for more information, including Academy programs on COVID-19, and links to the latest advisories from public health officials.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Microarrays, Immune Responses, and Vaccines

Edited by Edited by Luc Aujame and Nicolas Burdin (Aventis Pasteur, Marcy L'Etoile, France) and Betty Dodet and Marissa Vicari (Fondation Mérieux, Lyon, France)
Microarrays, Immune Responses, and Vaccines

Published: December 2002

Volume 975

Learn More

This Annals volume assesses the current impact of microarray technology on our knowledge and understanding of immunology, and on vaccine development. Questions that are addressed include the following: What microarray technological improvements remain to be achieved? What are the current biological limitations on generating new insights? In which areas should emphasis be placed in order to move ahead faster? How can the enormous amount of data generated be shared most effectively? Can we expect to be able to monitor antigen-specific immune responses, and, if so, what would be needed? What will be the impact of these technologies on vaccine development?